5-aza-2'-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy

International Journal of Gynecological Cancer

Volumn 22, Issue 6, 2012, Pages 951-959

  Hu, Qian ^a   Yu, Li ^a   Chen, Rui ^a   Wang, Yan Ling ^b   Ji, Lei ^b   Zhang, Yan ^a   Xie, Ya ^a   Liao, Qin Ping ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b INSTITUTE OF ZOOLOGY   (China)

Author keywords

5 aza 2' deoxycytidine; DNA methylation; Endometrial cancer; Medroxyprogesterone acetate; Progesterone receptor

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 5 AZA 2' DEOXYCYTIDINE; GELATINASE A; GELATINASE B; MEDROXYPROGESTERONE ACETATE; PROGESTERONE RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CELL CYCLE ARREST; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; ENDOMETRIUM CANCER; FLOW CYTOMETRY; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; METHYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ZYMOGRAPHY;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; AZACITIDINE; CARCINOMA; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE; NEOPLASM INVASIVENESS; RECEPTORS, PROGESTERONE;

EID: 84863620392     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182540160     Document Type: Article

References (30)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011. CA Cancer J Clin. 2011;61:212-236.
2. Chiva L, Lapuente F, González-Cortijo L, et al. Sparing fertility in young patients with endometrial cancer. Gynecol Oncol. 2008;111:S101YS104.
3. Kokka F, Brockbank E, Oram D, et al. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev. 2010;12:CD007926.
4. Punnonen R, Mattila J, Kuoppala T, et al. DNA ploidy, cell proliferation and steroid hormone receptors in endometrial hyperplasia and early adenocarcinoma. J Cancer Res Clin Oncol. 1993;119:426-429.
5. Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. Cancer. 1993;71:1467-1470.
6. Mortel R, Levy C, Wolff JP, et al. Female sex steroid receptors in postmenopausal endometrial carcinoma and biochemical response to an antiestrogen. Cancer Res. 1981;41:1140-1147.
7. Cirigliano M. Bioidentical hormone therapy: a review of the evidence. J Womens Health (Larchmt). 2007;16:600-631.
8. Tao MH, Freudenheim JL. DNA methylation in endometrial cancer. Epigenetics. 2010;5:491-498.
9. Ghabreau L, Roux JP, Niveleau A, et al. Correlation between the DNA global methylation status and progesterone receptor expression in normal endometrium, endometrioid adenocarcinoma and precursors. Virchows Arch. 2004;445:129-134.
10. Sasaki M, Dharia A, Oh BR, et al. Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. Cancer Res. 2001;61:97-102.
11. Stathis A, Hotte SJ, Chen EX, et al. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin Cancer Res. 2011;17:1582-1590.
12. Shang D, Liu Y, Liu Q, et al. Synergy of 5-aza-2'-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines. Cancer Lett. 2009;278:82-87.
13. Ishiguro M, Iida S, Uetake H, et al. Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15. Ann Surg Oncol. 2007;14:1752-1762.
14. Xie Y,Wang YL, Yu L, et al. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol. 2011;126:113-120.
15. Di Nezza LA, Misajon A, Zhang J, et al. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer. 2002;94:1466-1475.
16. Jabbour E, Issa JP, Garcia-Manero G, et al. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008;112:2341-2351.
17. Chen MY, Liao WS, Lu Z, et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer. 2011;117:4424-4438.
18. Zhu WG, Hileman T, Ke Y, et al. 5-aza-2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem. 2004;279:15161-15166.
19. Cui M, Wen Z, Chen J, et al. 5-Aza-2'-deoxycytidine is a potent inhibitor of DNA methyltransferase 3B and induces apoptosis in human endometrial cancer cell lines with the up-regulation of hMLH1. Med Oncol. 2010;27:278-285.
20. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A. 1994;91:11797-11801.
21. Vesely I, Chihak A. 5-Aza-2'-deoxycytidine: preclinical studies in mice. Neoplasma (Bratisi.). 1980;27:113-119.
22. Appleton K, Mackay HJ, Judson I, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. 2007;25:4603-4609.
23. Mukherjee K, Syed V, Ho SM. Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells. Oncogene. 2005;24:4388-4400.
24. Xiong Y, Dowdy SC, Gonzalez Bosquet J, et al. Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Gynecol Oncol. 2005;99:135-141.
25. Ren Y, Liu X, Ma D, et al. Down-regulation of the progesterone receptor by the methylation of progesterone receptor gene in endometrial cancer cells. Cancer Genet Cytogenet. 2007;175:107-116.
26. Sasaki M, Kaneuchi M, Fujimoto S, et al. Hypermethylation can selectively silence multiple promoters of steroid receptors in cancers. Mol Cell Endocrinol. 2003;202:201-207.
27. Lee K, Jeong J, Tsai MJ, et al. Molecular mechanisms involved in progesterone receptor regulation of uterine function. J Steroid Biochem Mol Biol. 2006;102:41-50.
28. Uchida H, Maruyama T, Nagashima T, et al. Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology. 2005;146:5365-5373.
29. Schneider-Stock R, Diab-Assef M, Rohrbeck A, et al. 5-Aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53-dependent mechanisms. J Pharmacol Exp Ther. 2005;312:525-536.
30. Murakami T, Li X, Gong J, et al. Induction of apoptosis by 5-azacytidine: drug concentration-dependent differences in cell cycle specificity. Cancer Res. 1995;55:3093-3098.